(Q34452066)

2 August 2017

1 reference

title

General aspects of anti-angiogenesis and cancer therapy (English)

1 reference

2 August 2017

1 reference

S K Libutti

1 reference

2 August 2017

T G Zogakis

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

Expert Opinion on Biological Therapy

2 August 2017

published in

1 reference

2 August 2017

1 reference

2 August 2017

1 reference

2 August 2017

page(s)

253-275

1 reference

Tumor angiogenesis: therapeutic implications

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Requirement of vascular integrin alpha v beta 3 for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Cloning, expression, and in vitro activity of human endostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Suramin: an anticancer drug with unique biological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

In vitro effect of suramin on lung tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Angiostatic effects of suramin analogs in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Interaction of angiogenesis inhibitor TNP-470 with basic fibroblast growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Inhibitory effect of TNP-470 on hepatic metastasis of mouse neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Inhibition of lymph node metastasis by an anti-angiogenic agent, TNP-470.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Inhibition of angiogenesis in vivo by interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Tumor targeting with a selective gelatinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Marimastat (BB2516): current status of development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Matrix metalloproteinases: biologic activity and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Matrix metalloproteinase inhibitors: applications in oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Activation of Type IV Procollagenases by Human Tumor-associated Trypsin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Inhibitory effects of CAI in glioblastoma growth and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Antiproliferative and antiinvasive effects of carboxyamido-triazole on breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Angiogenesis: role of calcium-mediated signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Matrix metalloproteinases in tumour invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

Matrix metalloproteinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.2.253

21 January 2018

Identifiers

DOI

10.1517/14712598.1.2.253

1 reference

2 August 2017

1 reference